from web site
The pharmaceutical landscape in Germany has actually seen a significant shift just recently with the introduction and rising popularity of GLP-1 (Glucagon-like peptide-1) receptor agonists. Originally developed to deal with Type 2 diabetes, medications like Ozempic and Wegovy have acquired international popularity for their weight-loss efficacy. For citizens and migrants in Germany, comprehending the expense, reimbursement structure, and availability of these drugs is necessary.
Germany runs under an unique two-tier healthcare system including statutory medical insurance (Gesetzliche Krankenversicherung or GKV) and personal health insurance (Private Krankenversicherung or PKV). This structure, combined with strict federal policies on pharmaceutical rates, makes the expense of GLP-1 medications in Germany quite various from that in the United States or other European countries.
GLP-1 receptor agonists are a class of medications that mimic a natural hormone in the body. They work by:
Common GLP-1 medications available in Germany consist of:
In Germany, the price of a medication is highly depending on whether it is being utilized for its main medical indicator (like Type 2 diabetes) or as a "way of life" treatment (like weight-loss).
If a client has Type 2 diabetes, the GKV generally covers the cost of medications like Ozempic or Rybelsus. In this case, the client pays just a little co-payment (Zuzahlung), typically varying from EUR5 to EUR10 per prescription.
However, for weight management, the scenario changes. Under Section 20 of the Social Code Book V (SGB V), medications mostly meant for "enhancing the quality of life" or weight-loss are presently omitted from GKV coverage. This indicates clients using Wegovy or Saxenda for weight-loss need to typically pay the full retail price out-of-pocket.
Private insurance providers have more flexibility. Depending upon the particular tariff and medical necessity, some private insurers might repay the cost of weight-loss medications if the patient meets particular requirements, such as a high BMI (usually >> 30 )and accompanying comorbidities (hypertension, sleep apnea).
The following table provides a quote of out-of-pocket expenses for the most popular GLP-1 medications in Germany as of late 2023/early 2024. Costs might vary somewhat in between pharmacies however are regulated by the Arzneimittelpreisverordnung (Medicines Price Ordinance).
| Medication | Main Usage | Type | Approx. Month-to-month Cost (Self-Pay) |
|---|---|---|---|
| Ozempic | Type 2 Diabetes | Weekly Injection | EUR80 - EUR90 |
| Wegovy (Low Dose) | Weight Loss | Weekly Injection | EUR170 - EUR190 |
| Wegovy (High Dose) | Weight Loss | Weekly Injection | EUR300 - EUR320 |
| Mounjaro | Diabetes/ Obesity | Weekly Injection | EUR260 - EUR330 |
| Saxenda | Weight reduction | Daily Injection | EUR250 - EUR300 |
| Rybelsus | Type 2 Diabetes | Daily Tablet | EUR100 - EUR140 |
Note: Costs represent the "Apothekenverkaufspreis" (Pharmacy Retail Price) for clients with a private prescription.
Wegovy was released in Germany in July 2023. Unlike the United States, where costs can go beyond ₤ 1,000 monthly, the German market take advantage of government-negotiated pricing, though it remains expensive for the typical consumer.
The cost of Wegovy in Germany scales somewhat with the dose. A standard 4-week supply includes one pen that enables four doses.
Normal Wegovy Price Tiers:
The variation between German and American drug costs is a frequent subject of dispute. The lower costs in Germany are credited to:
Despite whether a patient is paying out-of-pocket or through insurance coverage, GLP-1 medications are prescription-only (verschreibungspflichtig).
Germany, like the remainder of the world, has dealt with significant shortages of Ozempic. Since Ozempic is much less expensive than Wegovy (approx. EUR80 vs EUR170+), numerous clients sought "off-label" prescriptions for weight loss.
To combat this, the German Federal Institute for Drugs and Medical Devices (BfArM) has actually provided standards urging doctors to only prescribe Ozempic for its authorized indicator: Type 2 Diabetes. This is to make sure that diabetic patients do not lose access to their life-saving medication.
Presently, no. Wegovy is categorized as a "lifestyle drug" in Germany. Regardless of recent discussions in the Bundestag regarding the rising costs of weight problems, the statutory health insurance coverage funds are legally disallowed from covering obesity-only medications.
Yes. Any licensed drug store in Germany (including online pharmacies like DocMorris or Shop Apotheke) can fulfill a private prescription for GLP-1 medications, offered they have the stock.
Yes, Mounjaro was recently introduced in the German market. It is readily available in the "KwikPen" format. Costs are currently greater than Ozempic however competitive with Wegovy's upkeep doses.
Beyond the medication, clients need to account for the expense of the medical professional's consultation. For GKV clients, this is covered. For private/self-pay clients, a consultation can cost between EUR30 and EUR100 depending on the complexity of the test.
No. It is prohibited and extremely hazardous to acquire these medications without a prescription. Germany has stringent laws versus "Fernabsatz" (mail order) of prescription drugs from non-certified sources. Counterfeit Ozempic pens have been found in the European supply chain.
If you are thinking about GLP-1 therapy in Germany, keep the following points in mind:
The cost of GLP-1 medications in Germany reflects the country's broader method to health care: controlled, fairly economical compared to the worldwide market, however strictly partitioned in between medical necessity and elective treatment. While Mehr erfahren gain from really low co-payments, those seeking these drugs for weight loss should be prepared for a considerable monthly investment. As medical proof continues to reveal the long-lasting health benefits of weight reduction, lots of in the German medical community hope for a shift in insurance coverage legislation that might one day make these treatments more available to all.
